X
NICE rejects Opdivo in head and neck cancer – before it gains marketing approval
https://pharmaphorum.com/news/nice-rejects-opdivo-head-neck-cancer-gains-marketing-approval/
PD-L1
Avelumab filed, Pfizer and Merck prepare to join immunotherapy battle
Checkpoint inhibitor drug set to be fourth competitor in PD-1/PD-L1 market
